| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CLPT.2003.12.016 |
| P698 | PubMed publication ID | 15116054 |
| P2093 | author name string | Jessica Mwinyi | |
| Thomas Gerloff | |||
| Ivar Roots | |||
| Steffen Bauer | |||
| Andreas Johne | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 415-421 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics | |
| P478 | volume | 75 |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q90410126 | A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions |
| Q51272834 | A genetic risk score is significantly associated with statin therapy response in the elderly population. |
| Q28395802 | A mechanistic, model-based approach to safety assessment in clinical development |
| Q57314076 | Amiodarone Interacts with Simvastatin but not with Pravastatin Disposition Kinetics |
| Q46653214 | An association study of 43 SNPs in 16 candidate genes with atorvastatin response |
| Q46378129 | Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy |
| Q83145640 | Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia |
| Q84371927 | Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure |
| Q58594415 | Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia |
| Q37818151 | Clinical implications of pharmacogenetic variation on the effects of statins. |
| Q36426816 | Clinical implications of pharmacogenomics of statin treatment |
| Q38056878 | Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption |
| Q36303810 | Combinatorial pharmacogenetics |
| Q40135603 | Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations |
| Q51696345 | Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. |
| Q37960129 | Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions. |
| Q80997948 | Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy |
| Q57825140 | Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin |
| Q46813708 | Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide |
| Q38155016 | Drug interactions with statins |
| Q91620854 | Drug-drug-gene interactions and adverse drug reactions |
| Q35827882 | Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide |
| Q33776950 | Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants |
| Q37724381 | Efflux and uptake transporters as determinants of statin response. |
| Q93119620 | Enantiospecific Pharmacogenomics of Fluvastatin |
| Q38084901 | Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism |
| Q38155218 | Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin |
| Q34042444 | Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver |
| Q57825157 | Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population |
| Q36623470 | Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans |
| Q43940364 | Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q36998199 | Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 |
| Q39340828 | Global analysis of genetic variation in SLCO1B1. |
| Q37608527 | HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice |
| Q37680968 | Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects |
| Q36606137 | Hepatobiliary transporters and drug-induced cholestasis |
| Q38874111 | Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. |
| Q99604573 | Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers |
| Q36986507 | Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges |
| Q90484311 | Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia |
| Q34612244 | Impact of OATP transporters on pharmacokinetics |
| Q38663481 | Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. |
| Q38003174 | Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. |
| Q35915932 | Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions |
| Q53568394 | Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. |
| Q36687277 | Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans |
| Q52933882 | Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. |
| Q39034284 | Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). |
| Q37422685 | Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex |
| Q37728163 | Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients |
| Q39204093 | Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters |
| Q29616802 | Membrane transporters in drug development |
| Q54216256 | No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. |
| Q36536042 | No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone |
| Q40054814 | Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C. |
| Q57500316 | OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN-MEDIATED BILIRUBIN ELEVATION |
| Q37489569 | OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis |
| Q27001267 | OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies |
| Q39683666 | Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics |
| Q64932041 | Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology. |
| Q57500318 | Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients |
| Q37938905 | Overview of pharmacogenetics |
| Q37182212 | PhRMA white paper on ADME pharmacogenomics. |
| Q42726145 | PharmGKB very important pharmacogene: SLCO1B1. |
| Q34680467 | Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins |
| Q42936467 | Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q34777362 | Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney |
| Q35297067 | Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response |
| Q40225504 | Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations |
| Q37430401 | Pharmacogenetics of cardiovascular drug therapy |
| Q24676890 | Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy |
| Q37641869 | Pharmacogenetics of membrane transporters: an update on current approaches |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q35956177 | Pharmacogenetics-based new therapeutic concepts |
| Q31144283 | Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q36416907 | Pharmacogenomics of human OATP transporters |
| Q34787395 | Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin |
| Q46472687 | Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism |
| Q35827696 | Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes |
| Q33437736 | Prediction of hepatic clearance in human from in vitro data for successful drug development |
| Q54654987 | Rapid genotyping of the OATP1B1 polymorphisms A388G and T521C with real-time PCR FRET assays. |
| Q46974116 | Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q38001074 | Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review |
| Q37074085 | Role of OATP transporters in the disposition of drugs |
| Q36544966 | Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination |
| Q40180361 | Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics |
| Q41512597 | Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States |
| Q34579035 | SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers |
| Q36024636 | SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients |
| Q36184009 | SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. |
| Q44483899 | Safe and effective medicines for all: is personalized medicine the answer? |
| Q34574500 | Safety and efficacy of statins in Asians |
| Q35827517 | Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. |
| Q36192738 | Statin response and pharmacokinetics variants |
| Q33786577 | Synergistic interaction between genetics and disease on pravastatin disposition |
| Q36212769 | Systems-ADME/Tox: resources and network approaches |
| Q88910051 | The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics |
| Q37175829 | The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range |
| Q81241502 | The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1 |
| Q46607014 | The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite |
| Q37955160 | The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. |
| Q39349116 | The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. |
| Q34613443 | The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. |
| Q46878607 | The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics |
| Q37537018 | The role of transporters in the pharmacokinetics of orally administered drugs |
| Q46500452 | The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen |
| Q41706349 | Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations |
| Q37627544 | Transporter pharmacogenetics and statin toxicity |
| Q36985076 | Transporter-mediated uptake into cellular compartments |
| Q36123304 | Transporters and their impact on drug disposition |
| Q50641149 | Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. |
| Q33714593 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. |
| Q52936666 | [Implications of pharmacogenetics in every-day practice]. |
Search more.